NCT04409314View on ClinicalTrials.gov

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

CompletedOBSERVATIONAL
Enrollment

23

Participants

Timeline

Start Date

April 16, 2020

Primary Completion Date

August 9, 2023

Study Completion Date

August 9, 2023

Conditions
Recurrent Aggressive Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell LymphomaRecurrent Malignant NeoplasmRecurrent Plasma Cell MyelomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Aggressive Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory High Grade B-Cell LymphomaRefractory Malignant NeoplasmRefractory Plasma Cell MyelomaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Interventions
DRUG

Fluorine F 18-fluoroazomycin Arabinoside

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET scan

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT04409314 - Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy | Biotech Hunter | Biotech Hunter